- Home
- CCEC vs QURE Comparison
CCEC vs QURE Comparison
Compare CCEC & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | QURE |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | Greece | Netherlands |
| Employees | N/A | 248 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | CCEC | QURE |
|---|---|---|
| Price | $20.22 | $46.66 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $23.67 | ★ $45.00 |
| AVG Volume (30 Days) | 13.7K | ★ 2.0M |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | N/A | ★ 29.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,107,000.00 |
| Revenue This Year | $19.82 | $126.12 |
| Revenue Next Year | $39.95 | $200.43 |
| P/E Ratio | $4.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.77 | $8.73 |
| 52 Week High | $24.83 | $71.50 |
Technical Indicators
Market Signals| Indicator | CCEC | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 80.58 |
| Support Level | $20.05 | $21.63 |
| Resistance Level | $21.79 | $60.70 |
| Average True Range (ATR) | 0.93 | 2.41 |
| MACD | -0.28 | 1.75 |
| Stochastic Oscillator | 2.12 | 86.82 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.